Loading stock data…
$1.15-0.05 (-4.56%)
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
Radiopharm Theranostics Limited in the Healthcare sector is trading at $1.20 with a market capitalization of $35M. Wall Street consensus targets $16.99 (6 analysts), implying a +1315.8% move over the next 12 months. The stock is currently near its 52-week low of $1.00, remaining 69.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops sever...